As China’s biotech sector booms, companies and investors are increasingly turning to the Hong Kong Stock Exchange.
This past spring, the exchange put in place new rules designed to ease the way for pre-revenue biotechs to raise capital in Hong Kong. The hope was to attract a flood of listings from early-stage biotechs based both in China and in the U.S.
